The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor

Tumor therapy has evolved greatly since the discovery of immunotherapies. New therapies permit targeted approach with less side effects. Immunotherapies target specific components recognized on tumor cells, such as Programmed death-1 (PD-1). Overexpression of PD-1 markers in solid gastrointestinal t...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Attar, Layth, Truong, Phu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263492/
https://www.ncbi.nlm.nih.gov/pubmed/30510858
http://dx.doi.org/10.7759/cureus.2896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263492/
https://www.ncbi.nlm.nih.gov/pubmed/30510858
http://dx.doi.org/10.7759/cureus.2896

Ejemplares similares